Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | LYN | P07948 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ITK | Q08881 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.63 |
| ▸ | BLK | P51451 | 1/20 | 0.63 |
| ▸ | TEC | P42680 | 1/20 | 0.61 |
| ▸ | TXK | P42681 | 1/20 | 0.61 |
| ▸ | BMX | P51813 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827796 | 0.86 | BTK (0.74) | BTKLCKLYNEGFRITK | |
| SCHEMBL23409076 | 0.86 | BTK (0.74) | BTKLCKLYNEGFRITK | |
| SCHEMBL19831569 | 0.86 | BTK (0.70) | BTKLCKLYNEGFRITK | |
| SCHEMBL19649312 | 0.86 | BTK (0.81) | BTKLCKLYNEGFRITK | |
| SCHEMBL17951514 | 0.86 | BTK (0.81) | BTKLCKLYNEGFRITK | |
| SCHEMBL23223138 | 0.85 | BTK (0.68) | BTKLCKLYNEGFRITK | |
| SCHEMBL30615730 | 0.85 | BTK (0.75) | BTKLCKLYNEGFRITK | |
| SCHEMBL22625403 | 0.85 | BTK (0.71) | BTKLCKLYNEGFRITK | |
| SCHEMBL19519589 | 0.85 | BTK (0.71) | BTKLCKLYNEGFRITK | |
| SCHEMBL21398244 | 0.85 | BTK (0.73) | BTKLCKLYNEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | FLT3, FLT1, FGFR1 | BTK 32/4885LCK 114/4885LYN 145/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | BTK 35/4885LCK 148/4885LYN 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.